In addition, the knockout (KO) of m6A methyltransferase METTL3 or the use of inhibitor can also enrich immune pathway in tumour cells and upregulate the expression of antigen presentation, thereby enhancing the effect of ICB treatment.14, 15. The gene discussed is METTL3; the disease is neoplasm.